Context Therapeutics (CNTX) Guggenheim Inaugural Global Healthcare Conference summary

Strategic focus and recent developments

• Pursuing a roll-up strategy in T-cell engaging bispecific antibodies (TCEs) for solid tumors, with a focus on clinically validated ADC targets.

• Raised $100 million in May, expanding the pipeline to three drugs targeting Claudin 6, mesothelin, and Nectin-4.

• All assets are chosen for tumor-restricted targets with large market opportunities and lower safety risks.

• Well-funded with cash runway into 2027, aiming to remain an independent biotech.

Industry trends and clinical rationale

• Recent clinical successes in TCEs for solid tumors attributed to improved management of CRS via step dosing and prednisone premedication.

• High affinity CD3 payloads are linked to better efficacy, as seen in recent approvals and acquisitions in the space.

• Combining TCEs with ADCs is emerging as a key strategy, leveraging complementary mechanisms and resistance profiles.

• Notable industry deals include Merck’s acquisition of Harpoon and Amgen’s partnership for DLL3 TCE/ADC combinations.

Lead program: CTIM-76 (Claudin 6 TCE)

• Claudin 6 is an oncofetal protein, highly expressed in gynecologic cancers and absent from normal adult tissues.

• Preclinical studies show high potency and clean safety profile in animals; phase I to focus on ovarian and endometrial cancers.

• Initial clinical data expected in the first half of 2026, with efficacy anticipated at dose levels four and five.

• Success metrics include response rates above 35% in ovarian and 20–25% in endometrial cancers.

• Long-term goal is to develop and retain ownership of the asset, with potential for future partnerships.